Nonalcoholic hepatosteatotis
Conditions
Interventions
Experimental group:Benaglutide
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Men or woman aged 18 years and over; 2. Subjescts had been diagnosed with type 2 diabetes; 3. Hepatic fat content is >15% by 1H MRS within one month; 4. Elevated serum hepatic enzymes or hepatic fibrosis defined by Fibroscan.
Exclusion criteria
Exclusion criteria: 1. Alcohol excessive drinker defined as greater than 140g/w for men and 70g/w for women in the past 6 months; 2. Other liver diseases defined as alcoholic fatty liver disease, acute viral hepatitis, drug or auto immune hepatitis(AMA, SMA, ANA), cirrosis, liver cancer; 3. Biliary diseases including obstructive biliary diseases; 4. Endocrine disorders including hyperthyroidism, hypothyroidism, Cushing disease; 5. Poorly controlled diabetes defined as HbA1c greater than 9.5% within 3 months or use of anti-diabetic drugs such as pioglitazone, GLP-1RA,DPP-IV inhibitors; 6. Chronic kidney diseases or severe kidney injury defined as serum creatinine greater than 2.0mg/dL; 7. Serum ALT greater than 3 folds of normal range; 8. Poor health state with lifespan less than 5 years; 9. Pregnant women or plan to be pregnant in the near future; 10. Be unable to complete the study; 11. Continuous use of those drugs potentially associated with hepatitis including cortisone, methotrexate; 12. Participating other clinical trials within 4 weeks; 13. Be unable to sign consent forms.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of intrahepatic triglyceride contents and hepatic stiffness; | — |
Secondary
| Measure | Time frame |
|---|---|
| Body weight, waist circumference, fasting plasma glucose, HOMA-IR;Change of hepatic enzymes; | — |
Countries
China
Contacts
Public ContactXiaoying Li
Zhongshan Hospital, Fudan University
Outcome results
None listed